Caicun Zhou

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip, Nasser K. Altorki, Caicun Zhou et al. · The Lancet · 2021 · 1.5K citations

Medicine, Oncology, Pharmacology +13

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · The Lancet Respiratory Medicine · 2020 · 505 citations

Medicine, Oncology, Pharmacology +13

Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Tony Mok, Yi‐Long Wu, Jin Soo Lee et al. · Clinical Cancer Research · 2015 · 469 citations

Medicine, Oncology, Pharmacology +17

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 313 citations

Medicine, Oncology, Pharmacology +6

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim et al. · JAMA Oncology · 2021 · 289 citations · Full text

Medicine, Oncology, Pharmacology +15